Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh
NCT ID: NCT00607074
Last Updated: 2008-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
410 participants
INTERVENTIONAL
2003-06-30
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relative Efficacy of Two Regimens of Ante-helminthic Treatment
NCT00367627
The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas
NCT01314937
Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth
NCT01748929
Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance
NCT03465488
Study of Nitazoxanide in the Treatment of Amebiasis in Children
NCT00366730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
Anti-Giardia treatment only (secnidazole or albendazole)
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
Control group (placebo)
Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
Anti-Giardia treatment only (secnidazole or albendazole)
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
Control group (placebo)
Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3 Months
15 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cambridge
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Biological Anthropology, University of Cambridge
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicholas C Mascie-Taylor, ScD
Role: STUDY_CHAIR
Department of Biological Anthropology, University of Cambridge
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Preventive and Social Medicine
Mohakhali, Dhaka Division, Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Goto R, Mascie-Taylor CG, Lunn PG. Impact of anti-Giardia and anthelminthic treatment on infant growth and intestinal permeability in rural Bangladesh: a randomised double-blind controlled study. Trans R Soc Trop Med Hyg. 2009 May;103(5):520-9. doi: 10.1016/j.trstmh.2008.07.020. Epub 2008 Sep 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BMRC/ERC/2001-2004/2281
Identifier Type: -
Identifier Source: secondary_id
BMRC/ERC/2001-2004/2281
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.